PMC:4235387 / 18393-21737 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4235387","sourcedb":"PMC","sourceid":"4235387","source_url":"http://www.ncbi.nlm.nih.gov/pmc/4235387","text":"Symptoms of depression and anxiety\nThe changes in severity of depressive and anxiety symptoms as measured by HAM-D24, HAM-A, and CGI-S during the double-blind phase and the open-label extension phase are summarized in Table 5 and Figs 3–5. These results indicate that the improvements achieved during the double-blind phase were maintained when study participants were continued on or switched to vortioxetine, with scores decreasing further from the open-label baseline values irrespective of the original double-blind assigned treatment. For example, the mean (±SD) HAM-D24 scores decreased from 31.2 (±5.5) at the double-blind lead-in baseline to 17.6 (±9.4) at the open-label baseline, with a further improvement to 9.7 (±8.2) at the final visit (OC analysis). These results reflect a total mean change from double-blind baseline to the end point of the open-label study of –21.5 (±9.4) (Fig. 3). Response (defined as a ≥50% decrease in the HAM-D24 score from the open-label baseline to the final visit) was achieved in 423/829 (51.0%) study participants (OC analysis). Improvements in HAM-D24 scores were evident irrespective of the dosage assignment in the lead-in trial (i.e. there was no difference in response rates on the basis of treatment in the lead-in study). Decreases in HAM-D24 scores ranged from 16.2 to 25.0 across all vortioxetine dose groups relative to the double-blind baseline, with a further improvement of 4.0–10.2 points at the final visit relative to the open-label baseline. Remission, defined as a HAM-D17 total score of up to 7, was achieved in 461/829 (55.6%) study participants at the final visit. These overall improvements in HAM-D24 scores were similar to those observed in the subgroup of study participants who received duloxetine during the double-blind trial (US study). Here, that subgroup showed a decrease of 18.2 points at the final visit relative to the double-blind baseline and a decrease of 3.4 points relative to the open-label baseline.\nTable 5 Efficacy measures\nFig. 3 Mean HAM-D24 total scores by study visit. BL, baseline; HAM-D24, 24-item Hamilton Depression Scale.\nFig. 4 Mean HAM-A total scores by study visit. BL, baseline; HAM-A, Hamilton Anxiety Scale.\nFig. 5 Mean CGI-S total scores by study visit. BL, baseline; CGI-S, Clinical Global Impressions Scale – Severity of Illness Scale. Similar changes in symptom severity were noted for the MADRS total score, MADRS response (defined as a ≥50% decrease in the total score from baseline), and MADRS remission (defined as a total score≤10). Mean changes in HAM-A and CGI-S scores from double-blind baseline to the final visit were –12.4 (±7.4) and –2.5 (±1.3) points, respectively, among those treated with vortioxetine, with decreases continuing after the initiation of the open-label phase (Table 5 and Figs 4 and 5). For the double-blind duloxetine group, the improvement in HAM-A and CGI-S scores was –9.5 (±6.88) and –2.18 (±1.255) points, respectively. For patient-reported outcomes, study participants receiving vortioxetine experienced improvements in all SF-36 subscale scores from open-label baseline for all previous treatment groups. Similarly, study participants experienced improvements from double-blind baseline and open-label baseline in the mean SDS scores and in individual items, indicating continued improvement.","divisions":[{"label":"Title","span":{"begin":0,"end":34}},{"label":"Table caption","span":{"begin":1987,"end":2015}},{"label":"Figure caption","span":{"begin":2014,"end":2123}},{"label":"Figure caption","span":{"begin":2122,"end":2216}},{"label":"Figure caption","span":{"begin":2215,"end":2348}}],"tracks":[{"project":"NEUROSES","denotations":[{"id":"T544","span":{"begin":153,"end":158},"obj":"PATO_0001177"},{"id":"T545","span":{"begin":312,"end":317},"obj":"PATO_0001177"},{"id":"T546","span":{"begin":514,"end":519},"obj":"PATO_0001177"},{"id":"T547","span":{"begin":624,"end":629},"obj":"PATO_0001177"},{"id":"T548","span":{"begin":819,"end":824},"obj":"PATO_0001177"},{"id":"T549","span":{"begin":1386,"end":1391},"obj":"PATO_0001177"},{"id":"T550","span":{"begin":1787,"end":1792},"obj":"PATO_0001177"},{"id":"T551","span":{"begin":1906,"end":1911},"obj":"PATO_0001177"},{"id":"T552","span":{"begin":2603,"end":2608},"obj":"PATO_0001177"},{"id":"T553","span":{"begin":2846,"end":2851},"obj":"PATO_0001177"},{"id":"T554","span":{"begin":3224,"end":3229},"obj":"PATO_0001177"},{"id":"T555","span":{"begin":159,"end":164},"obj":"PATO_0000083"},{"id":"T556","span":{"begin":194,"end":199},"obj":"PATO_0000083"},{"id":"T557","span":{"begin":318,"end":323},"obj":"PATO_0000083"},{"id":"T558","span":{"begin":2797,"end":2802},"obj":"PATO_0000083"},{"id":"T559","span":{"begin":173,"end":177},"obj":"PATO_0000610"},{"id":"T560","span":{"begin":451,"end":455},"obj":"PATO_0000610"},{"id":"T561","span":{"begin":669,"end":673},"obj":"PATO_0000610"},{"id":"T562","span":{"begin":858,"end":862},"obj":"PATO_0000610"},{"id":"T563","span":{"begin":968,"end":972},"obj":"PATO_0000610"},{"id":"T564","span":{"begin":1483,"end":1487},"obj":"PATO_0000610"},{"id":"T565","span":{"begin":1966,"end":1970},"obj":"PATO_0000610"},{"id":"T566","span":{"begin":2786,"end":2790},"obj":"PATO_0000610"},{"id":"T567","span":{"begin":3102,"end":3106},"obj":"PATO_0000610"},{"id":"T568","span":{"begin":3243,"end":3247},"obj":"PATO_0000610"},{"id":"T569","span":{"begin":456,"end":461},"obj":"CHEBI_35209"},{"id":"T570","span":{"begin":674,"end":679},"obj":"CHEBI_35209"},{"id":"T571","span":{"begin":863,"end":868},"obj":"CHEBI_35209"},{"id":"T572","span":{"begin":973,"end":978},"obj":"CHEBI_35209"},{"id":"T573","span":{"begin":1488,"end":1493},"obj":"CHEBI_35209"},{"id":"T574","span":{"begin":1971,"end":1976},"obj":"CHEBI_35209"},{"id":"T575","span":{"begin":2791,"end":2796},"obj":"CHEBI_35209"},{"id":"T576","span":{"begin":3107,"end":3112},"obj":"CHEBI_35209"},{"id":"T577","span":{"begin":3248,"end":3253},"obj":"CHEBI_35209"},{"id":"T578","span":{"begin":397,"end":409},"obj":"CHEBI_76016"},{"id":"T579","span":{"begin":1338,"end":1350},"obj":"CHEBI_76016"},{"id":"T580","span":{"begin":2718,"end":2730},"obj":"CHEBI_76016"},{"id":"T581","span":{"begin":3030,"end":3042},"obj":"CHEBI_76016"},{"id":"T582","span":{"begin":583,"end":592},"obj":"PATO_0001997"},{"id":"T583","span":{"begin":630,"end":634},"obj":"CHEBI_25016"},{"id":"T584","span":{"begin":1163,"end":1167},"obj":"CHEBI_25016"},{"id":"T585","span":{"begin":1258,"end":1262},"obj":"CHEBI_25016"},{"id":"T586","span":{"begin":630,"end":634},"obj":"CHEBI_27889"},{"id":"T587","span":{"begin":1163,"end":1167},"obj":"CHEBI_27889"},{"id":"T588","span":{"begin":1258,"end":1262},"obj":"CHEBI_27889"},{"id":"T589","span":{"begin":1758,"end":1768},"obj":"CHEBI_36796"},{"id":"T590","span":{"begin":2852,"end":2862},"obj":"CHEBI_36796"},{"id":"T591","span":{"begin":2863,"end":2868},"obj":"CHEBI_24433"},{"id":"T592","span":{"begin":3275,"end":3278},"obj":"CHEBI_8984"}],"attributes":[{"subj":"T544","pred":"source","obj":"NEUROSES"},{"subj":"T545","pred":"source","obj":"NEUROSES"},{"subj":"T546","pred":"source","obj":"NEUROSES"},{"subj":"T547","pred":"source","obj":"NEUROSES"},{"subj":"T548","pred":"source","obj":"NEUROSES"},{"subj":"T549","pred":"source","obj":"NEUROSES"},{"subj":"T550","pred":"source","obj":"NEUROSES"},{"subj":"T551","pred":"source","obj":"NEUROSES"},{"subj":"T552","pred":"source","obj":"NEUROSES"},{"subj":"T553","pred":"source","obj":"NEUROSES"},{"subj":"T554","pred":"source","obj":"NEUROSES"},{"subj":"T555","pred":"source","obj":"NEUROSES"},{"subj":"T556","pred":"source","obj":"NEUROSES"},{"subj":"T557","pred":"source","obj":"NEUROSES"},{"subj":"T558","pred":"source","obj":"NEUROSES"},{"subj":"T559","pred":"source","obj":"NEUROSES"},{"subj":"T560","pred":"source","obj":"NEUROSES"},{"subj":"T561","pred":"source","obj":"NEUROSES"},{"subj":"T562","pred":"source","obj":"NEUROSES"},{"subj":"T563","pred":"source","obj":"NEUROSES"},{"subj":"T564","pred":"source","obj":"NEUROSES"},{"subj":"T565","pred":"source","obj":"NEUROSES"},{"subj":"T566","pred":"source","obj":"NEUROSES"},{"subj":"T567","pred":"source","obj":"NEUROSES"},{"subj":"T568","pred":"source","obj":"NEUROSES"},{"subj":"T569","pred":"source","obj":"NEUROSES"},{"subj":"T570","pred":"source","obj":"NEUROSES"},{"subj":"T571","pred":"source","obj":"NEUROSES"},{"subj":"T572","pred":"source","obj":"NEUROSES"},{"subj":"T573","pred":"source","obj":"NEUROSES"},{"subj":"T574","pred":"source","obj":"NEUROSES"},{"subj":"T575","pred":"source","obj":"NEUROSES"},{"subj":"T576","pred":"source","obj":"NEUROSES"},{"subj":"T577","pred":"source","obj":"NEUROSES"},{"subj":"T578","pred":"source","obj":"NEUROSES"},{"subj":"T579","pred":"source","obj":"NEUROSES"},{"subj":"T580","pred":"source","obj":"NEUROSES"},{"subj":"T581","pred":"source","obj":"NEUROSES"},{"subj":"T582","pred":"source","obj":"NEUROSES"},{"subj":"T583","pred":"source","obj":"NEUROSES"},{"subj":"T584","pred":"source","obj":"NEUROSES"},{"subj":"T585","pred":"source","obj":"NEUROSES"},{"subj":"T586","pred":"source","obj":"NEUROSES"},{"subj":"T587","pred":"source","obj":"NEUROSES"},{"subj":"T588","pred":"source","obj":"NEUROSES"},{"subj":"T589","pred":"source","obj":"NEUROSES"},{"subj":"T590","pred":"source","obj":"NEUROSES"},{"subj":"T591","pred":"source","obj":"NEUROSES"},{"subj":"T592","pred":"source","obj":"NEUROSES"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"NEUROSES","color":"#93ecc7","default":true}]}]}}